|
1
|
Bagchi A and Mills AA: The quest for the
1p36 tumor suppressor. Cancer Res. 68:2551–2556. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Reisman D, Glaros S and Thompson EA: The
SWI/SNF complex and cancer. Oncogene. 28:1653–1668. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wu JN and Roberts CW: ARID1A mutations in
cancer: Another epigenetic tumor suppressor? Cancer Discov.
3:35–43. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Guan B, Gao M, Wu CH, Wang TL and Shih IM:
Functional analysis of in-frame indel ARID1A mutations reveals new
regulatory mechanisms of its tumor suppressor functions. Neoplasia.
14:986–993. 2012.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Samartzis EP, Noske A, Dedes KJ, Fink D
and Imesch P: ARID1A mutations and PI3K/AKT pathway alterations in
endometriosis and endometriosis-associated ovarian carcinomas. Int
J Mol Sci. 14:18824–18849. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang X, Nagl NG Jr, Flowers S, Zweitzig D,
Dallas PB and Moran E: Expression of p270 (ARID1A), a component of
human SWI/SNF complexes, in human tumors. Int J Cancer.
112(636)2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Flores-Alcantar A, Gonzales-Sandoval A,
Escalante-Alcalde D and Lomeli H: Dynamics of expression of ARID1A
and ARID1B subunits in mouse embryos and in cells during the cell
cycle. Cell Tissue Res. 345:137–148. 2011.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A in
ovarian clear cell carcinoma. Science. 330:228–231. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jones S, Meng L, Parsons DW, Zhang X,
Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D,
et al: Somatic mutations in the chromatin remodeling gene ARID1A
occur in several tumor types. Hum Mutat. 33:100–103.
2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Luchini C, Veronese N, Solmi M, Cho H, Kim
JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, et al: Prognostic
role and implications of mutation status of tumor suppressor gene
ARID1A in cancer: A systematic review and meta-analysis.
Oncotarget. 6:39088–39097. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mao TL and Shih IeM: The roles of ARID1A
in gynecologic cancer. J Gynecol Oncol. 24:376–381. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wu RC, Wang TL and Shih IeM: The emerging
roles of ARID1A in tumor suppression. Cancer Biol Ther. 15:655–664.
2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lyu C, Zhang Y, Zhou X and Lang J: ARID1A
gene silencing reduces the sensitivity of ovarian clear cell
carcinoma to cisplastin. Exp Ther Med. 12:4067–4071.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gregory SL, Kortschak DR, Kallionis B and
Saint R: Characterization of the dead ringer gene identifies a
novel, highly conserved family of sequence-specific DNA-binding
proteins. Mol Cell Biol. 16:792–799. 1996.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Herrscher RF, Kaplan MH, Lelsz DL, Das C,
Scheuermann R and Tucker PW: The immunoglobulin heavy-chain
matrix-associating regions are bound by Bright: A B cell-specific
trans-activator that describes a new DNA-binding protein family.
Genes Dev. 9:3067–3082. 1995.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Patsialou A, Wilsker D and Moran E:
DNA-binding properties of ARID family proteins. Nucleic Acids Res.
33:66–80. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dallas PB, Pacchione S, Wilsker D, Bowrin
V, Kobayashi R and Moran E: The human SWI-SNF complex protein p270
is an ARID family member with non-sequence-specific DNA binding
activity. Mol Cell Biol. 20:3137–3146. 2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wang X, Haswell JR and Roberts CW:
Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated
in cancer-mechanisms and potential therapeutic insights. Clin
Cancer Res. 20:21–27. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Carlson M, Osmond BC and Botstein D:
Mutants of yeast defective in sucrose utilization. Genetics.
98:25–40. 1981.PubMed/NCBI
|
|
21
|
Wilsker D, Patsialou A, Zumbrun SD, Kim S,
Chen Y, Dallas PB and Moran E: The DNA-binding properties of the
ARID-containing subunits of yeast and mammalian SWI/SNF complexes.
Nucleic Acids Res. 32:1345–1353. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kwon H, Imbalzano AN, Khavari PA, Kingston
RE and Green MR: Nucleosome disruption and enhancement of activator
binding by a human SWI/SNF complex. Nature. 370:477–481.
1994.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li XS, Trojer P, Matsumura T, Treisman JE
and Tanese N: Mammalian SWI/SNF-a subunit BAF250/ARID1 is an E3
ubiquitin ligase that targets histone H2B. Mol Cell Biol.
30:1673–1688. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Narlicar GJ, Sundaramoorthy R and
Owen-Hughes T: Mechanisms and functions of ATP-dependent
chromatin-remodeling enzymes. Cell. 154:490–503. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Smith CL and Peterson CL: A conserved
Swi2/Snf2 ATPase motif couples ATP hydrolysis to chromatin
remodeling. Mol Cell Biol. 25:5880–5892. 2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Becker PB: Nucleosome sliding: Facts and
fiction. EMBO J. 21:4749–4753. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cairns BR: Chromatin remodeling: Insights
and intrigue from single-molecule studies. Nat Struct Mol Biol.
14:989–996. 2007.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hargreaves DC and Crabtree GR:
ATP-dependent chromatin remodeling: Genetics, genomics and
mechanisms. Cell Res. 21:396–420. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Vignali M, Hassan AH, Neely KE and Workman
JL: ATP-dependent chromatin-remodeling complexes. Mol Cell Biol.
20:1899–1910. 2000.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Schnitzler G, Sif S and Kingston RE: Human
SWI/SNF interconverts a nucleosome between its base state and a
stable remodeled state. Cell. 94:17–27. 1998.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Imbalzano AN, Kwon H, Green MR and
Kingston RE: Facilitated binding of TATA-binding protein to
nucleosomal DNA. Nature. 370:481–485. 1994.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Bartolomew B: Regulating the chromatin
landscape: Structural and mechanistic perspectives. Annu Rev
Biochem. 83:671–696. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Jeong KW, Lee YH and Stallcup MR:
Recruitment of the SWI/SNF chromatin remodeling complex to steroid
hormone-regulated promoters by nuclear receptor coactivator
flightless-I. J Biol Chem. 284:29298–29309. 2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ronan JL, Wu W and Crabtree GR: From
neural development to cognition: Unexpected roles for chromatin.
Nat Rev Genet. 14:347–359. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Decristofaro MF, Betz BL, Rorie CJ,
Reisman DN, Wang W and Weissman BE: Characterization of SWI/SNF
protein expression in human breast cancer cell lines and other
malignancies. J Cell Physiol. 186:136–145. 2001.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Inoue H, Furukawa T, Giannakopoulos S,
Zhou S, King DS and Tanese N: Largest subunits of the human SWI/SNF
chromatin-remodeling complex promote transcriptional activation by
steroid hormone receptors. J Biol Chem. 277:41674–41685.
2002.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Kadoch C, Hargreaves DC, Hodges C, Elias
L, Ho L, Ranish J and Crabtree GR: Proteomic and bioinformatic
analysis of mammalian SWI/SNF complexes identifies extensive roles
in human malignancy. Nat Genet. 45:592–601. 2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Keenen B, Qi H, Saladi SV, Yeung M and de
la Serna IL: Heterogeneous SWI/SNF chromatin remodeling complexes
promote expression of microphthalmia-associated transcription
factor target genes in melanoma. Oncogene. 29:81–92.
2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Tang L, Nogales E and Ciferri C: Structure
and function of SWI/SNF chromatin remodeling complexes and
mechanistic implications for transcription. Prog Biophys Mol Biol.
102:122–128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nie Z, Xue Y, Yang D, Zhou S, Deroo BJ,
Archer TK and Wang W: A specificity and targeting subunit of a
human SWI/SNF family-related chromatin-remodeling complex. Mol Cell
Biol. 20:8879–8888. 2000.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Takao C, Morikawa A, Ohkubo H, Kito Y,
Saigo K, Sakuratami T, Futamura M, Takeuchi T and Yoshida K:
Downregulation of ARID1A, a component of the SWI/SNF chromatin
remodeling complex, in breast cancer. J Cancer. 8:1–8.
2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Inoue H, Giannakopoulos S, Parkhurst CN,
Matsumura T, Kono EA, Furukawa T and Tanese N: Target genes of the
largest human SWI/SNF complex subunit control cell growth. Biochem
J. 434:83–92. 2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Dechassa ML, Zhang B, Horowitz-Scherer R,
Persinger J, Woodcock CL, Peterson CL and Bartholomew B:
Architecture of the SWI/SNF-nucleosome complex. Mol Cell Biol.
28:6010–6021. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Nagl NG Jr, Wang X, Patsialou A, Van Scoy
M and Moran E: Distinct mammalian SWI/SNF chromatin remodeling
complexes with opposing roles in cell-cycle control. EMBO J.
26:752–763. 2007.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang X, Nagl NG, Wilsker D, Van Scoy M,
Pacchione S, Yaciuk P, Dallas PB and Moran E: Two related ARID
family proteins are alternative subunits of human SWI/SNF
complexes. Biochem J. 383:319–325. 2004.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Yan HB, Wang XF, Zhang Q, Tang ZQ, Jiang
YH, Fan HZ, Sun Y, Yang PY and Liu F: Reduced expression of the
chromatin remodeling gene ARID1A enhances gastric cancer cell
migration and invasion via downregulation of E-cadherin
transcription. Carcinogenesis. 35:867–876. 2014.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Saghafinia S, Mina M, Riggi N, Hanahan D
and Ciriello G: Pan-cancer landscape of aberrant DNA methylation
across human tumors. Cell Rep. 25:1066–1080.e8. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kamińska K, Nalejska E, Kubiak M,
Wojtysiak J, Żołna Ł, Kowalewski J and Lewandowska MA: Prognostic
and predictive epigenetic biomarkers in oncology. Mol Diagn Ther.
23:83–95. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Tsai HC and Baylin SB: Cancer epigenetics:
Linking basic biology to clinical medicine. Cell Res. 21:502–517.
2011.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Heinz S, Romanoski CE, Benner C and Glass
CK: The selection and function of cell type-specific enhancers. Nat
Rev Mol Cell Biol. 16:144–154. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Tillo D, Kaplan N, Moore IK,
Fondufe-Mittendorf Y, Gossett AJ, Field Y, Lieb JD, Widom J, Segal
E and Hughes TR: High nucleosome occupancy is encoded at human
regulatory sequences. PLoS One. 5(e9129)2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Sun X, Chuang JC, Kanchwala M, Wu L, Celen
C, Li L, Liang H, Zhang S, Maples T, Nguyen LH, et al: Suppression
of the SWI/SNF component Arid1a promotes mammalian regeneration.
Cell Stem Cell. 18:456–466. 2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wu S, Zhang R and Bitler BG: Arid1a
controls tissue regeneration. Stem Cell Investig.
3(35)2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lei I, West J, Yan Z, Gao X, Fang P,
Dennis JH, Gnatovskiy L, Wang W, Kingston RE and Wang Z: BAF250a
protein regulates nucleosome occupancy and histone modifications in
priming embryonic stem cell differentiation. J Biol Chem.
290:19343–19352. 2015.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Gao X, Tate P, Hu P, Tjian R, Skarnes WC
and Wang Z: ES cell pluripotency and germ-layer formation require
the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad
Sci USA. 105:6656–6661. 2008.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Han L, Madan V, Mayakonda A, Dakle P, Woon
TW, Shyamsunder P, Nordin HBM, Cao Z, Sundaresan J, Lei I, et al:
Chromatin remodeling mediated by ARID1A is indispensable for normal
hematopoiesis in mice. Leukemia. 33:2291–2305. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Hota SK, Johnson JR, Verschueren E, Thomas
R, Blotnick AM, Zhu Y, Sun X, Pennacchio LA, Krogan NJ and Bruneau
BG: Dynamic BAF chromatin remodeling complex subunit inclusion
promotes temporally distinct gene expression programs in
cardiogenesis. Development. 146(pii: dev174086)2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Lei I, Gao X, Sham MH and Wang Z: SWI/SNF
protein component BAF250a regulates cardiac progenitor cell
differentiation by modulating chromatin accessibility during second
heart field development. J Biol Chem. 287:24255–24262.
2012.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Watanabe R, Ui A, Kanno S, Ogiwara H,
Nagase T, Kohno T and Yasui A: SWI/SNF factors required for
cellular resistance to DNA damage include ARID1A and ARID1B and
show interdependent protein stability. Cancer Res. 74:2465–2475.
2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Shen J, Peng Y, Wei L, Zhang W, Yang L,
Lan L, Kapoor P, Ju Z, Mo Q, Shih IM, et al: ARID1A deficiency
impairs the DNA damage checkpoint and sensitizes cells to PARP
inhibitors. Cancer Discov. 5:752–767. 2015.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Lakshminarasimhan R, Andreu-Vieyra C,
Lawrenson K, Duymich CE, Gayther SA, Liang G and Jones PA:
Down-regulation of ARID1A is sufficient to initiate neoplastic
transformation along with epigenetic reprogramming in
non-tumorigenic endometriotic cells. Cancer Lett. 401:11–19.
2017.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Miranda TB and Jones PA: DNA methylation:
The nuts and bolts of repression. J Cell Physiol. 213:384–390.
2007.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Jang HS, Shin WJ, Lee JE and Do JT: CpG
and Non-CpG methylation in epigenetic gene regulation and brain
function. Genes (Basel). 8(pii: E148)2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Herman JG, Latif F, Weng Y, Lerman MI,
Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al:
Silencing of the VHL tumor-suppressor gene by DNA methylation in
renal carcinoma. Proc Natl Acad Sci USA. 91:9700–9704.
1994.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Baylin SB, Makos M, Wu JJ, Yen RW, De
Bustros A, Vertino P and Nelkin BD: Abnormal patterns of DNA
methylation in human neoplasia: Potential consequences for tumor
progression. Cancer Cells. 3:383–390. 1991.PubMed/NCBI
|
|
66
|
Makos M, Nelkin BD, Lerman MI, Latif F,
Zbar B and Baylin SB: Distinct hypermethylation patterns occur at
altered chromosome loci in human lung and colon cancer. Proc Natl
Acad Sci USA. 89:1929–1933. 1992.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Qu Y, Dang S and Hou P: Gene methylation
in gastric cancer. Clin Chim Acta. 424:53–65. 2013.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia
B, Liang X, Wei W, Sun S, Zhang Y, et al: Promoter hypermethylation
of ARID1A gene is responsible for its low mRNA expression in many
invasive breast cancers. PLoS One. 8(e53931)2013.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Aso T, Uozaki H, Morita S, Kumagai A and
Watanabe M: Loss of ARID1A, ARID1B, and ARID2 expression during
progression of gastric cancer. Anticancer Res. 35:6819–6827.
2015.PubMed/NCBI
|
|
70
|
Xie H, Chen P, Huang HW, Liu LP and Zhao
F: Reactive oxygen species downregulate ARID1A expression via its
promoter methylation during the pathogenesis of endometriosis. Eur
Rev Med Pharmacol Sci. 21:4509–4515. 2017.PubMed/NCBI
|
|
71
|
Ibragimova I, Maradeo ME, Dulaimi E and
Cairns P: Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2,
KDM6A and other chromatin-modifying genes is absent or rare in
clear cell RCC. Epigenetics. 8:486–493. 2013.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Xiao W, Lou N, Ruan H, Bao L, Xiong Z,
Yuan C, Tong J, Xu G, Zhou Y, Qu Y, et al: Mir-144-3p promotes cell
proliferation, metastasis, sunitinib resistance in clear cell renal
cell carcinoma by downregulating ARID1A. Cell Physiol Biochem.
43:2420–2433. 2017.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854.
1993.PubMed/NCBI View Article : Google Scholar
|
|
74
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531.
2004.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Yang F, Xu Y, Liu C, Ma C, Zou S, Xu X,
Jia J and Liu Z: NF-κB/miR-223-3p/ARID1A axis is involved in
Helicobacter pylori CagA-induced gastric carcinogenesis and
progression. Cell Death Dis. 9(12)2018.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Lu WC, Liu CJ, Tu HF, Chung YT, Yang CC,
Kao SY, Chang KW and Lin SC: miR-31 targets ARID1A and enhances the
oncogenicity and stemness of head and neck squamous cell carcinoma.
Oncotarget. 7:57254–57267. 2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Wang N, Zhou Y, Zheng L and Li H: MiR-31
is an independent prognostic factor and functions as an oncomir in
cervical cancer via targeting ARID1A. Gynecol Oncol. 134:129–137.
2014.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Yang Y, Zhao X and Li HX: MiR-221 and
miR-222 simultaneously target ARID1A and enhance proliferation and
invasion of cervical cancer cells. Eur Rev Med Pharmacol Sci.
20:1509–1515. 2016.PubMed/NCBI
|
|
80
|
Li ZY, Zhu SS, Chen XJ, Zhu J, Chen Q,
Zhang YQ, Zhang CL, Guo TT and Zhang LM: ARID1A suppresses
malignant transformation of human pancreatic cells via mediating
senescence-associated miR-503/CDKN2A regulatory axis. Biochem
Biophys Res Commun. 493:1018–1025. 2017.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Kim YS, Jeong H, Choi JW, Oh HE and Lee
JH: Unique characteristics of ARID1A mutation and protein level in
gastric and colorectal cancer: A meta-analysis. Saudi J
Gastroenterol. 23:268–274. 2017.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Lichner Z, Scorilas A, White NM, Girgis
AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D and Yousef
GM: The chromatin remodeling gene ARID1A is a new prognostic marker
in clear cell carcinoma. Am J Pathol. 182:1163–1170.
2013.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Takeda T, Banno K, Okawa R, Yanokura M,
Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K,
et al: ARID1A gene mutation in ovarian and endometrial cancers
(Review). Oncol Rep. 35:607–613. 2016.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Dawson MA and Kouzarides T: Cancer
epigenetics: From mechanism to therapy. Cell. 150:12–27.
2012.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Okawa R, Banno K, Iida M, Yanokura M,
Takeda T, Iijima M, Kunitomi-Irie H, Nakamura K, Adachi M, Umene K,
et al: Aberrant chromatin remodeling in gynecological cancer. Oncol
Lett. 14:5107–5113. 2017.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Wang Y, Wysocka J, Perlin JR, Leonelli L,
Allis CD and Coonrod SA: Linking covalent histone modifications to
epigenetics: The rigidity and plasticity of the marks. Cold Spring
Harb Symp Quant Biol. 69:161–169. 2004.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Guan B, Mao TL, Panuganti PK, Kuhn E,
Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL and Shih IeM: Mutation
and loss of expression of ARID1A in uterine low-grade endometrioid
carcinoma. Am J Surg Pathol. 35:625–632. 2011.PubMed/NCBI View Article : Google Scholar
|
|
88
|
He F, Li J, Xu JF, Zhang S, Xu Y, Zhao W,
Yin Z and Wang X: Decreased expression of ARID1A associates with
poor prognosis and promotes metastases of hepatocellular carcinoma.
J Exp Clin Cancer Res. 34(47)2015.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Kim KJ, Jung HY, Oh MH, Cho H, Lee JH, Lee
HJ, Jang SH and Lee MS: Loss of ARID1A expression in gastric
cancer: Correlation with mismatch repair deficiency and
clinicopathologic features. J Gastric Cancer. 15:201–208.
2015.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Mamo A, Cavallone L, Tuzmen S, Chabot C,
Ferrario C, Hassan S, Edgren H, Kalliomeni O, Aleynikova O,
Przybytkowski E, et al: An integrated genomic approach identifies
ARID1A as a candidate tumor-suppressor gene in breast cancer.
Oncogene. 31:2090–2100. 2012.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Bosse T, ter Haar NT, Seeber LM, v Diest
PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H and Smit
VT: Loss of ARID1A expression and its relationship with PI3K-Akt
pathway alterations, TP53 and microsatellite instability in
endometrial cancer. Mod Pathol. 26:1525–1535. 2013.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Lee D, Yu EJ, Ham IH, Hur H and Kim YS:
AKT-inhibition is an effective treatment strategy in
ARID1A-deficient gastric cancer cells. Onco Targets Ther.
10:4153–4159. 2017.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Samartzis EP, Gutsche K, Dedes KJ, Fink D,
Stucki M and Imesch P: Loss of ARID1A expression sensitizes cancer
cells to PI3K- and AKT-inhibition. Oncotarget. 5:5295–5303.
2014.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Guan B, Wang TL and Shih IeM: ARID1A, a
factor that promotes formation of SWI/SNF-mediated chromatin
remodeling, is a tumor suppressor in gynecologic cancers. Cancer
Res. 71:6718–6727. 2011.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Shain AH, Giacomini CP, Matsukuma K,
Karikari CA, Bashyam MD, Hidalgo M, Maitra A and Pollack JR:
Convergent structural alterations define SWItch/Sucrose
NonFermentable (SWI/SNF) chromatin remodeler as a central tumor
suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA.
109:E252–E259. 2012.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Xiao W, Awadallah A and Xin W: Loss of
ARID1A/BAF250a expression in ovarian endometriosis and clear cell
carcinoma. Int J Clin Exp Pathol. 5:642–650. 2012.PubMed/NCBI
|
|
97
|
Dykhuizen EC, Hargreaves DC, Miller EL,
Cui K, Korshunov A, Kool M, Pfister S, Cho YJ, Zhao K and Crabtree
GR: BAF complexes facilitate decatenation of DNA by topoisomerase
IIα. Nature. 497:624–627. 2013.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Bochar DA, Wang L, Beniya H, Kinev A, Xue
Y, Lane WS, Wang W, Kashanchi F and Shiekhattar R: BRCA1 is
associated with a human SWI/SNF-related complex: Linking chromatin
remodeling to breast cancer. Cell. 102:257–265. 2000.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Putra J and Suriawinata AA: Clinical
significance of loss of ARID1A expression in colorectal and small
intestinal carcinoma. Clin Transl Gastroenterol.
6(e131)2015.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes of
gastric cancer. Nat Genet. 43:1219–1223. 2011.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Cho H, Kim JS, Chung H, Perry C, Lee H and
Kim JH: Loss of ARID1A/BAF250a expression is linked to tumor
progression and adverse prognosis in cervical cancer. Hum Pathol.
44:1365–1374. 2013.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Ishikawa M, Ishibashi T, Iida K, Otsuki Y, Nakayama
S and Miyazaki K: Frequent loss of tumor suppressor ARID1A protein
expression in adenocarcinomas/adenosquamous carcinomas of the
uterine cervix. Int J Gynecol Cancer. 22:208–212. 2012.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Ayhan A, Mao TL, Seckin T, Wu CH, Guan B,
Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih
IeM: Loss of ARID1A expression is an early molecular event in tumor
progression from ovarian endometriotic cyst to clear cell and
endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315.
2012.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: Loss of ARID1A protein expression occurs as an early
event in ovarian clear-cell carcinoma development and frequently
coexists with PIK3CA mutations. Mod Pathol. 25:615–624.
2012.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Yang L, Wei S, Zhao R, Wu Y, Qiu H and
Xiong H: Loss of ARID1A expression predicts poor survival prognosis
in gastric cancer: A systematic meta-analysis from 14 studies. Sci
Rep. 6(28919)2016.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Ahn DH, Javle M, Ahn CW, Jain A, Mikhail
S, Noonan AM, Ciombor K, Wu C, Shroff R, Chen JL and Bekaii-Saab T:
Next-generation sequencing survey of biliary tract cancer reveals
the association between tumor somatic variants and chemotherapy
resistance. Cancer. 122:3657–3666. 2016.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Balbás-Martinez C, Rodriguez-Pinilla M,
Casanova A, Dominguez O, Pisano DG, Gómez G, Lloreta J, Lorente JA,
Malats N and Real FX: ARID1A alterations are associated with
FGFR3-wild type, poor-prognosis, urothelial bladder tumors. PLoS
One. 8(e62483)2013.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Cho HD, Lee JE, Jung HY, Oh MH, Lee JH,
Jang SH, Kim KJ, Han SW, Kim SY, Kim HJ, et al: Loss of tumor
supressor ARID1A protein expression correlates with poor prognosis
in patients with primary breast cancer. J Breast Cancer.
18:339–346. 2015.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Drage MG, Tippayawong M, Agoston TA, Zheng
Y, Bueno R, Hornick JL, Odge RD and Srivastava A: Morphological
features and prognostic significance of ARID1A-deficient esophageal
adenocarcinomas. Arch Pathol Lab Med. 141:970–977. 2017.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Faraj SF, Chaux A, Gonzales-Roibon N,
Munari E, Ellis C, Driscoll T, Schoenberg MP, Bivalacqua TJ, Shih
IeM and Netto GJ: ARID1A immunohistochemistry improves outcome
prediction in invasive urothelial carcinoma of urinary bladder. Hum
Pathol. 45:2233–2239. 2014.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Wang DD, Chen YB, Pan K, Wang W, Chen SP,
Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ and Wang QJ: Decreased
expression of the ARID1A gene is associated with poor prognosis in
primary gastric cancer. PLoS One. 7(e40364)2012.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Wei XL, Wang DS, Xi SY, Wu WJ, Chen DL,
Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, et al: Clinicopathologic
and prognostic relevance of ARID1A protein loss in colorectal
cancer. World J Gastroenterol. 20:18404–18412. 2014.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Wiegand KC, Hennesy BT, Leung S, Wang Y,
Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, et
al: A functional proteogenomic analysis of endometrioid and clear
cell carcinomas using reverse phase protein array and mutation
analysis: Protein expression is histotype-specific and loss of
ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer.
14(120)2014.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Cajuso T, Hӓnninen UA, Kondelin J, Gylfe
AE, Tanskanen T, Katainen R, Pitkӓnen E, Ristolainen H, Kaasinen E,
Taipale M, et al: Exome sequencing reveals frequent inactivating
mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite
unstable colorectal cancer. Int J Cancer. 135:611–623.
2014.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Wiegand KC, Sy K, Kalloger SE, Li-Chang H,
Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ,
et al: ARID1A/BAF250a as a prognostic marker for gastric carcinoma:
A study of 2 cohorts. Hum Pathol. 45:1258–1268. 2014.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Zhang L, Wang C, Yu S, Jia C, Yan J, Lu Z
and Chen J: Loss of ARID1A expression correlates with tumor
differentiation and tumor progression stage in pancreatic ductal
adenocarcinoma. Technol Cancer Res Treat.
17(1533034618754475)2018.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Tan ZX, Liu HJ and Hou B: Decreased
expression of ARID1A is related to the poor prognosis of glioma
patients. Int J Clin Exp Pathol. 9:2009–2014. 2016.
|
|
118
|
Nastase A, Teo JY, Heng HL, Ng CC, Myint
SS, Rajaseragan V, Loh JL, Lee SY, Ooi LL, Chung AY, et al: Genomic
and proteomic characterization of ARID1A chromatin remodeller in
ampullary tumors. Am J Cancer Res. 7:484–502. 2017.PubMed/NCBI
|
|
119
|
Itamochi H, Oumi N, Oishi T, Shoji T,
Fujiwara J, Sugiyama T, Suzuki M, Kigawa J and Harada T: Loss of
ARID1A expression is associated with poor prognosis in patients
with stage I/II clear cell carcinoma of the ovary. Int J Clin
Oncol. 20:967–973. 2015.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao
S, Wu R, Chen C, Li X, Zhou L, et al: Frequent mutations of
chromatin remodeling genes in transitional cell carcinoma of the
bladder. Nat Genet. 43:875–878. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
121
|
Jiao Y, Pawlik TM, Anders RA, Selaru FM,
Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani
, et al: Exome sequencing identifies frequent inactivating
mutations in BAP1, ARID1A and PBRM1 in intrahepatic
cholangiocarcinomas. Nat Genet. 45:1470–1473. 2013.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Sausen M, Leary RJ, Jones S, Wu J,
Reynolds PC, Liu X, Blackford A, Parmigiani G, Diaz LA Jr,
Papadopoulos N, et al: Integrated genomic analyses identify ARID1A
and ARID1B alterations in the childhood cancer neuroblastoma. Nat
Genet. 45:12–17. 2013.PubMed/NCBI View Article : Google Scholar
|
|
123
|
Illumina: An introduction to
Next-Generation Sequencing Technology. Illumina, Inc., 2017.
https://www.illumina.com/documents/products/illumina_sequencing_introduction.pdf.
|
|
124
|
Zhou X, Ren L, Meng Q, Li Y, Yu Y and Yu
J: The next-generation sequencing technology and application.
Protein Cell. 6:520–536. 2010.PubMed/NCBI View Article : Google Scholar
|
|
125
|
Huang HN, Lin MC, Huang WC, Chiang YC and
Kuo KT: Loss of ARID1A expression and its relationship with
PI3K-Akt pathway alterations and ZNF217 amplification in ovarian
clear cell carcinoma. Mod Pathol. 27:983–990. 2014.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Lai CR, Hsu CY, Chen YJ, Yen MS, Chao KC
and Li AF: Ovarian cancers arising from endometriosis: A
microenvironmental biomarker study including ER, HNF1ß, p53, PTEN,
BAF250a, and COX-2. J Chin Med Assoc. 76:629–634. 2013.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Lowery WJ, Schildkraut JM, Akushevich L,
Bentley R, Marks JR, Huntsman D and Berchuck A: Loss of
ARID1A-associated protein expression is a frequent event in clear
cell and endometrioid ovarian cancers. Int J Gynecol Cancer.
22:9–14. 2012.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Maeda D, Mao TL, Fukayama M, Nakagawa S,
Yano T, Taketani Y and Shih leM: Clinicopathological significance
of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma.
Int J Mol Sci. 11:5120–5128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Wu RC, Ayhan A, Maeda D, Kim KR, Clarke
BA, Shaw P, Chui MH, Rosen B, Shih leM and Wang TL: Frequent
somatic mutations of the telomerase reverse transcriptase promoter
in ovarian clear cell carcinoma but not in other major types of
gynecologic malignancies. J Pathol. 232:473–481. 2014.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Yamamoto S, Tsuda H, Takano M, Tamai S and
Matsubara O: PIK3CA mutations and loss of ARID1A protein expression
are early events in the development of cystic ovarian clear cell
adenocarcinoma. Virchows Arch. 460:77–87. 2012.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Murakami R, Matsumura N, Brown JB, Higasa
K, Tsutsumi T, Kamada M, Abou-Taleb H, Hosoe Y, Kitamura S,
Yamaguchi K, et al: Exome sequencing landscape analysis in ovarian
clear cell carcinoma shed light on key chromosomal regions and
mutation gene networks. Am J Pathol. 187:2246–2258. 2017.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:282–288. 2012.PubMed/NCBI View Article : Google Scholar
|
|
133
|
Samartzis EP, Samartzis N, Noske A, Fedier
A, Caduff R, Dedes KJ, Fink D and Imesch P: Loss of
ARID1A/BAF250a-expression in endometriosis: A biomarker for risk of
carcinogenic transformation? Mod Pathol. 25:885–892.
2012.PubMed/NCBI View Article : Google Scholar
|
|
134
|
McConechy MK, Ding J, Senz J, Yang W,
Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP,
et al: Ovarian and endometrial endometrioid carcinomas have
distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 27:128–134.
2014.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Wu CH, Mao TL, Vang R, Ayhan A, Wang TL,
Kurman RJ and Shih leM: Endocervical-type mucinous borderline
tumors are related to endometrioid tumors based on mutation and
loss of expression of ARID1A. Int J Gynecol Pathol. 31:297–303.
2012.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Choi JY, Han HH, Kim YT, Lee JH, Kim BG,
Kang S and Cho NH: Ovarian clear cell carcinoma sub-typing by
ARID1A expression. Yonsei Med J. 58:59–66. 2017.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Yokoyama Y, Matsushita Y, Shigeto T,
Futagami M and Mizunuma H: Decreased ARID1A expression is
correlated with chemoresistance in epithelial ovarian cancer. J
Gynecol Oncol. 25:58–63. 2014.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Cancer Genome Atlas Research Network,
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature 497: 67-73,
2013.
|
|
139
|
Liang H, Cheung LW, Li J, Ju Z, Yu S,
Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome
sequencing combined with functional genomics reveals novel
candidate driver cancer genes in endometrial cancer. Genome Res.
22:2120–2129. 2012.PubMed/NCBI View Article : Google Scholar
|
|
140
|
Fadare O, Renshaw IL and Liang SX: Does
the loss of ARID1A (BAF-250a) expression in endometrial clear cell
carcinomas have any clinicopathological significance? A pilot
assessment. J Cancer. 3:129–136. 2012.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Fadare O, Gwin K, Desouki MM, Crispens MA,
Jones HW III, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL
and Parkash V: The clinicopathologic significance of p53 and
BAF-250a (ARID1A) expression in clear cell carcinoma of the
endometrium. Mod Pathol. 26:1101–1110. 2013.PubMed/NCBI View Article : Google Scholar
|
|
142
|
Werner HM, Berg A, Wik E, Birkeland E,
Krakstad C, Kusonmano K, Petersen K, Kalland KH, Oyan AM, Akslen
LA, et al: ARID1A loss is prevalent in endometrial hyperplasia with
atypia and low-grade endometrioid carcinomas. Mod Pathol.
26:428–434. 2013.PubMed/NCBI View Article : Google Scholar
|
|
143
|
Wiegand KC, Lee AF, Al-Agha OM, Chow C,
Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B
and Huntsman DG: Loss of BAF250a (ARID1A) is frequent in high-grade
endometrial carcinomas. J Pathol. 224:328–333. 2011.PubMed/NCBI View Article : Google Scholar
|
|
144
|
Rahman M, Nakayama K, Rahman MT, Katagiri
H, Katagiri A, Ishibashi T, Ishikawa M, Iida K and Miyazaki K:
Clinicopathologic analysis of loss of AT-Rich interactive domain 1A
expression in endometrial cancer. Hum Pathol. 44:103–109.
2013.PubMed/NCBI View Article : Google Scholar
|
|
145
|
Cornen S, Adelaide J, Bertucci F, Finetti
P, Guille A, Birnbaum DJ, Birnbaum D and Chaffanet M: Mutations and
deletions of ARID1A in breast tumors. Oncogene. 31:4255–4256.
2012.PubMed/NCBI View Article : Google Scholar
|
|
146
|
Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji
H, Ma Y, Yao G, Jiang Y, Shan M, et al: Frequent low expression of
chromatin remodeling gene ARID1A in breast cancer and its clinical
significance. Cancer Epidemiol. 36:288–293. 2012.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Zhao J, Liu C and Zhao Z: ARID1A: A
potential prognostic factor for breast cancer. Tumour Biol.
35:4813–4819. 2014.PubMed/NCBI View Article : Google Scholar
|
|
148
|
Ünçel M, Diniz G, Aköz G, Ekin ZY, Sayhan
S, Yardım S and Salimoğlu S: Loss of nuclear ARID-1A expressions is
associated with hormone receptor status in breast cancers. Eur J
Breast Health. 15:125–129. 2019.PubMed/NCBI View Article : Google Scholar
|
|
149
|
Momozawa Y, Iwasaki Y, Parsons MT,
Kamatani Y, Takahashi A, Tamura C, Katagiri T, Yoshida T, Nakamura
S, Sugano K, et al: Germline pathogenic variants of 11 breast
cancer genes in 7,051 Japanese patients and 11,241 controls. Nat
Commun. 9(4083)2018.PubMed/NCBI View Article : Google Scholar
|
|
150
|
Rajendran KB and Deng C: Characterization
of potential driver mutations involved in human breast cancer by
computational approaches. Oncotarget. 8:50252–50272.
2017.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Abe H, Maeda D, Hino R, Otake Y, Isogai M,
Ushiku AS, Matsusaka K, Kunita A, Ushiku T, Uozaki H, et al: ARID1A
expression loss in gastric cancer: Pathway-dependent roles with and
without Epstein-Barr virus infection and microsatellite
instability. Virchows Arch. 461:367–377. 2012.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Han N, Kim MA, Lee HS and Kim WH: Loss of
ARID1A expression is related to gastric cancer progression,
Epstein-Barr Virus infection, and mismatch repair deficiency. Appl
Immunohistochem Mol Morphol. 24:320–325. 2016.PubMed/NCBI View Article : Google Scholar
|
|
154
|
Ibarrola-Villava M, Llorca-Cardeñosa MJ,
Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S,
Navarro S, Ribas G and Cervantes A: Deregulation of ARID1A, CDH1,
cMET and PIK3CA and target-related microRNA expression in gastric
cancer. Oncotarget. 6:26935–26945. 2015.PubMed/NCBI View Article : Google Scholar
|
|
155
|
Kim YB, Ham IH, Hur H and Lee D: Various
ARID1A expression patterns and their clinical significance in
gastric cancers. Hum Pathol. 49:61–70. 2016.PubMed/NCBI View Article : Google Scholar
|
|
156
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120.
2012.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Fujimoto A, Totoki Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya M, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 44:760–764. 2012.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Guichard C, Amaddeo G, Imbeaud S, Ladeiro
Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M,
Degos F, et al: Integrated analysis of somatic mutations and focal
copy-number changes identifies key genes and pathways in
hepatocellular carcinoma. Nat Genet. 44:694–698. 2012.PubMed/NCBI View Article : Google Scholar
|
|
159
|
Streppel MM, Lata S, DelaBastide M,
Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink
FH, Offerhaus GJ, et al: Next-generation sequencing of endoscopic
biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's
esophagus. Oncogene. 33:347–357. 2014.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Lee SY, Kim DW, Lee HS, Ihn MH, Oh HK,
Park DJ, Kim HH and Kang SB: Loss of AT-rich interactive domain 1A
expression in gastrointestinal malignancies. Oncology. 88:234–240.
2015.PubMed/NCBI View Article : Google Scholar
|
|
161
|
Sen M, Wang X, Hamdan FH, Rapp J, Eggert
J, Kosinsky RL, Wegwitz F, Kutschat AP, Younesi FS, Gaedcke J, et
al: ARID1A facilitates KRAS signaling-regulated enhancer activity
in an AP1-dependent manner in colorectal cancer cells. Clin
Epigenet. 11(92)2019.PubMed/NCBI View Article : Google Scholar
|
|
162
|
Guo G, Sun X, Chen C, Wu S, Huang P, Li Z,
Dean M, Huang Y, Jia W, Zhou Q, et al: Whole-genome and whole-exome
sequencing of bladder cancer identifies frequent alterations in
genes involved in sister chromatid cohesion and segregation. Nat
Genet. 45:1459–1463. 2013.PubMed/NCBI View Article : Google Scholar
|
|
163
|
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao
Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, et al: MYD88
L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J
Med. 367:826–833. 2012.PubMed/NCBI View Article : Google Scholar
|
|
164
|
Giulino-Roth L, Wang K, MacDonald TY,
Mathew S, Tam Y, Cronin MT, Palmer G, Lucena-Silva N, Pedrosa F,
Pedrosa M, et al: Targeted genomic sequencing of pediatric Burkitt
lymphoma identifies recurrent alterations in antiapoptotic and
chromatin-remodeling genes. Blood. 120:5181–5184. 2012.PubMed/NCBI View Article : Google Scholar
|
|
165
|
Weaver IC, Korgan AC, Lee K, Wheeler RV,
Hundert AS and Goguen D: Stress and the emerging roles of chromatin
remodeling in signal integration and stable transmission of
reversible phenotypes. Front Behav Neurosci. 11(41)2017.PubMed/NCBI View Article : Google Scholar
|
|
166
|
Bitler BG, Wu S, Park PH, Hai Y, Aird KM,
Wang Y, Zhai Y, Kossenkov AV, Vara-Ailor A, Rauscher FJ III, et al:
ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell
Biol. 19:962–973. 2017.PubMed/NCBI View Article : Google Scholar
|
|
167
|
Bitler BG, Aird KM, Garipov A, Li H,
Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM,
Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2
methyltransferase activity in ARID1A-mutated cancers. Nat Med.
21:231–238. 2015.PubMed/NCBI View Article : Google Scholar
|
